Skip to content
Screener

Biodesix, Inc. BDSX Q1 2025 earnings

Reported May 13, 2025 · After market close

Revenue$18.0MMiss by $4.6M
EPS-$0.08In line
Revenue estimate$22.6M
EPS estimate-$0.08

Next report

Nov 5, 2026 (In 3 days)
Revenue estimate$27.5M
EPS estimate-$0.75

Financials

Q1 2025

Income statement

See full
Revenue$18.0M+21.2%
Operating income-$9.1M+17.1%
Net income-$11.1M+18.5%
EPS (diluted)-$1.52-986%

Balance sheet

See full
Cash & equivalents$17.6M+53.2%
Total debt$62.3M+1.9%
Total equity$11.1M+301%
Total assets$86.2M-1.1%

Cash flow

See full
Operating cash flow-$8.6M+43.8%
CapEx$74.0K-68.4%
Free cash flow-$8.7M+44.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$91.27M-34.3%
Enterprise value$135.93M-27.9%
P/S1.2×-1.3×

Profitability

See full
Operating margin-43.8%-10.9pp
Net margin-54.3%-14.6pp
FCF margin-60.4%-13.2pp

Returns & leverage

See full
Debt / equity5.6×—
Current ratio2.2×+1.3×

Segments

By product

See full
Diagnostic Tests$16.3M+18.3%
Development Services$1.6M+60.7%

FAQ

When did Biodesix, Inc. report Q1 2025 earnings?
Biodesix, Inc. (BDSX) reported Q1 2025 earnings on May 13, 2025 after market close.
What were Biodesix, Inc.'s Q1 2025 revenue and EPS?
Biodesix, Inc. reported revenue of $18.0M and eps of $-0.08 for Q1 2025.
Did Biodesix, Inc. beat estimates in Q1 2025?
Revenue missed the consensus estimate of $22.6M by $4.6M. EPS beat the consensus estimate of $-0.08 by $0.00.
How did Biodesix, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 21.2% from $14.8M a year earlier and eps grew 42.9% from $-0.14.
Where can I find Biodesix, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-070292) and the 10-Q periodic report (0000950170-25-070339) directly on SEC EDGAR. The filing index links above go to sec.gov.